Advise Taking "Flozins" in the Morning
Jardiance (jar-DEE-ans, empagliflozin) will be the third SGLT2 inhibitor...after Invokana (canagliflozin) and Farxiga (dapagliflozin).
These "flozins" increase glucose excretion by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
They all lower A1C by about 0.7% to 1%...reduce weight by 4 to 7 pounds...lower systolic BP by 3 to 5 mmHg...and rarely cause hypoglycemia.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote